Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings.


Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
08 2021
Historique:
received: 19 08 2020
accepted: 18 11 2020
revised: 03 11 2020
pubmed: 9 1 2021
medline: 28 1 2022
entrez: 8 1 2021
Statut: ppublish

Résumé

Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = -0.45 to -0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = -0.14 to -0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = -0.88 to -0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = -0.13 to -0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = -0.21 to -0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.

Identifiants

pubmed: 33414498
doi: 10.1038/s41380-020-00969-z
pii: 10.1038/s41380-020-00969-z
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4529-4543

Subventions

Organisme : Medical Research Council
ID : MR/J008915/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Investigateurs

Maria Calem (M)
Stefania Tognin (S)
Gemma Modinos (G)
Sara Pisani (S)
Tamar C Kraan (TC)
Daniella S van Dam (DS)
Nadine Burger (N)
G Paul Amminger (GP)
Athena Politis (A)
Joanne Goodall (J)
Stefan Borgwardt (S)
Erich Studerus (E)
Ary Gadelha (A)
Elisa Brietzke (E)
Graccielle Asevedo (G)
Elson Asevedo (E)
Andre Zugman (A)
Tecelli Domínguez-Martínez (T)
Manel Monsonet (M)
Paula Cristóbal-Narváez (P)
Anna Racioppi (A)
Thomas R Kwapil (TR)
Mathilde Kazes (M)
Claire Daban (C)
Julie Bourgin (J)
Olivier Gay (O)
Célia Mam-Lam-Fook (C)
Dorte Nordholm (D)
Lasse Rander (L)
Kristine Krakauer (K)
Louise Birkedal Glenthøj (LB)
Birte Glenthøj (B)
Dominika Gebhard (D)
Julia Arnhold (J)
Joachim Klosterkötter (J)
Iris Lasser (I)
Bernadette Winklbaur (B)

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psy. 2013;70:1107–12.
Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Critical Rev Neurobiol. 2000;14:1–21.
doi: 10.1615/CritRevNeurobiol.v14.i1.10
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, D.C.: American Psychiatric Association; 2013.
World Health Organization. International classification of diseases, 11th revision (ICD-11). ICD-11 is here Geneva: World Health Organization; 2018.
Becker H, Nieman D, Wiltink S, Dingemans P, Van de Fliert J, Velthorst E, et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? Psych Med. 2010;40:1599–606.
doi: 10.1017/S0033291710000048
Mollon J, Mathias SR, Knowles EE, Rodrigue A, Koenis MM, Pearlson GD, et al. Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders. Psychol Med. 2019;50:48–57.
pubmed: 30606277 pmcid: 7086288 doi: 10.1017/S0033291718003938
Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust NZealand J Psych. 2011;45:93–108.
doi: 10.3109/00048674.2010.541418
Zanelli J, Mollon J, Sandin S, Morgan C, Dazzan P, Pilecka I, et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am J Psychiatry. 2019;176:811–9.
pubmed: 31256609 doi: 10.1176/appi.ajp.2019.18091088
Harvey PD. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry. 2014;75:34–38.
pubmed: 24919170 doi: 10.4088/JCP.13065su1.08
Kodesh A, Goldberg Y, Rotstein A, Weinstein G, Reichenberg A, Sandin S, et al. Risk of dementia and death in very-late-onset schizophrenia-like psychosis: a national cohort study. Schizophrenia Res. 2020;223:220–6.
doi: 10.1016/j.schres.2020.07.020
Mollon J, David AS, Zammit S, Lewis G, Reichenberg A. Course of cognitive development from infancy to early adulthood in the psychosis spectrum. JAMA Psychiatry. 2018;75:270–9.
pubmed: 29387877 pmcid: 5885954 doi: 10.1001/jamapsychiatry.2017.4327
Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psyc. 2010;167:160–9.
doi: 10.1176/appi.ajp.2009.09040574
Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. Microstructural maturation of the human brain from childhood to adulthood. Neuroimage. 2008;40:1044–55.
pubmed: 18295509 doi: 10.1016/j.neuroimage.2007.12.053
Snitz BE, MacDonald III AW, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2005;32:179–94.
pubmed: 16166612 doi: 10.1093/schbul/sbi048
Agnew-Blais J, Seidman LJ. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn Neuropsychiatry. 2013;18:44–82.
pubmed: 22998599 doi: 10.1080/13546805.2012.676309
van Os J, van der Steen Y, Islam MA, Guloksuz S, Rutten BP, Simons CJ, et al. Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. Psychol Med. 2017;47:2421–37.
pubmed: 28436345 doi: 10.1017/S0033291717000915
Sorensen HJ, Debost JC, Agerbo E, Benros ME, McGrath JJ, Mortensen PB, et al. Polygenic risk scores, school achievement, and risk for schizophrenia: a danish population-based study. Biol Psychiatry. 2018;84:684–91.
pubmed: 29807621 doi: 10.1016/j.biopsych.2018.04.012
Kuepper R, van Os J, Lieb R, Wittchen H-U, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. Bmj. 2011;342:d738.
pubmed: 21363868 pmcid: 3047001 doi: 10.1136/bmj.d738
EU-GEI. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophrenia Bulletin. 2014;40:729–36.
doi: 10.1093/schbul/sbu069
Gayer-Anderson C, Jongsma HE, Di Forti M, Quattrone D, Velthorst E, de Haan L, et al. The EUropean Network of National Schizophrenia networks studying gene–environment interactions (EU-GEI): incidence and first-episode case–control programme. Social Psych Psych Epidemiol. 2020:55:645–57.
doi: 10.1007/s00127-020-01831-x
Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L, Investigators G. Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene–environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psych Res. 2012;21:205–21.
doi: 10.1002/mpr.1352
Blyler CR, Gold JM, Iannone VN, Buchanan RW. Short form of the WAIS-III for use with patients with schizophrenia. Schizophrenia Res. 2000;46:209–15.
doi: 10.1016/S0920-9964(00)00017-7
Velthorst E, Levine SZ, Henquet C, de Haan L, van Os J, Myin-Germeys I, et al. To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia—a control-case family study. Cog Neuropsych. 2013;18:574–93.
doi: 10.1080/13546805.2012.731390
Mallet J. MRC sociodemographic schedule. Section of Social Psychiatry, Institute of Psychiatry; 1997.
WHO. Composite international diagnostic interview. Geneva, Switzerland: World Health Organization; 1990.
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psych. 2009;195:488–91.
doi: 10.1192/bjp.bp.109.064220
McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psych. 1991;48:764–70.
doi: 10.1001/archpsyc.1991.01810320088015
Craddock N, Asherson P, Owen MJ, Williams J, Mcguffin P, Farmer AE. Concurrent validity of the OPCRIT diagnostic system: comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses. Br J Psych. 1996;169:58–63.
doi: 10.1192/bjp.169.1.58
Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, et al. Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). Schizophrenia Res. 2005;80:117–30.
doi: 10.1016/j.schres.2005.04.018
Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF). Br J Psych. 1995;166:654–9.
doi: 10.1192/bjp.166.5.654
StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp; 2017. https://www.stata.com/features/documentation/ . Accessed on 1 March 2018.
R-Core-Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http://www.R-project.org .
Wickham H. ggplot2: Elegant graphics for data analysis. New York: Springer-Verlag; 2016.
doi: 10.1007/978-3-319-24277-4
Zalesky A, Pantelis C, Cropley V, Fornito A, Cocchi L, McAdams H, et al. Delayed development of brain connectivity in adolescents with schizophrenia and their unaffected siblings. JAMA Psychiatry. 2015;72:900–8.
pubmed: 26176706 doi: 10.1001/jamapsychiatry.2015.0226
Flynn JR. What is intelligence?: Beyond the Flynn effect. Cambridge, UK: Cambridge University Press; 2007.
Salthouse TA. When does age-related cognitive decline begin? Neurobiol Aging. 2009;30:507–14.
pubmed: 19231028 pmcid: 2683339 doi: 10.1016/j.neurobiolaging.2008.09.023
Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, et al. Age-associated cognitive decline. Br Med Bull. 2009;92:135–52.
pubmed: 19776035 doi: 10.1093/bmb/ldp033
Dutton E, van der Linden D, Lynn R. The negative Flynn Effect: a systematic literature review. Intelligence. 2016;59:163–9.
doi: 10.1016/j.intell.2016.10.002
Teasdale TW, Owen DR. A long-term rise and recent decline in intelligence test performance: the Flynn Effect in reverse. Pers Ind Diff. 2005;39:837–43.
doi: 10.1016/j.paid.2005.01.029
Bratsberg B, Rogeberg O. Flynn effect and its reversal are both environmentally caused. Proc Nat Acad Sci. 2018;115:6674–8.
pubmed: 29891660 pmcid: 6042097 doi: 10.1073/pnas.1718793115
Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, et al. Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med. 2011;155:300–8.
pubmed: 21893623 doi: 10.7326/0003-4819-155-5-201109060-00007
Dickinson D. Digit symbol coding and general cognitive ability in schizophrenia: worth another look? Br J Psychiatry. 2008;193:354–6.
pubmed: 18978311 doi: 10.1192/bjp.bp.108.049387
Smeland OB, Frei O, Kauppi K, Hill WD, Li W, Wang Y, et al. Identification of genetic loci jointly influencing schizophrenia risk and the cognitive traits of verbal-numerical reasoning, reaction time, and general cognitive function. JAMA Psychiatry. 2017;74:1065–75.
pubmed: 28746715 pmcid: 5710474 doi: 10.1001/jamapsychiatry.2017.1986
Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez N, Kalapurakkel S, et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Transl Psychiatry. 2018;8:78.
pubmed: 29643358 pmcid: 5895806 doi: 10.1038/s41398-018-0124-8
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35:573–88.
pubmed: 20620163 doi: 10.1016/j.neubiorev.2010.07.001
Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 2004;72:21–28.
pubmed: 15531404 doi: 10.1016/j.schres.2004.09.008
Goldstein JM, Cherkerzian S, Tsuang MT, Petryshen TL. Sex differences in the genetic risk for schizophrenia: History of the evidence for sex‐specific and sex‐dependent effects. Am J Med Gen Part B: Neuropsych Genetics. 2013;162:698–710.
doi: 10.1002/ajmg.b.32159
Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009;3:53.
pubmed: 19956405 pmcid: 2786315 doi: 10.3389/neuro.09.053.2009
van Winkel R, Investigators G. Further evidence that cannabis moderates familial correlation of psychosis-related experiences. PLoS One. 2015;10:e0137625.
pubmed: 26384217 pmcid: 4575144 doi: 10.1371/journal.pone.0137625
Van Haren NEM, Van Dam DS, Stellato RK. Genetic risk and outcome of psychosis (group) investigators. Change in IQ in schizophrenia patients and their siblings: a controlled longitudinal study. Psychol Med. 2019;49:2573–81.
pubmed: 30674361 doi: 10.1017/S0033291718003537
Knowles EEM, Mathias SR, Pearlson GD, Barrett J, Mollon J, Denbow D, et al. Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence. Schizophr Res. 2019;206:333–46.
pubmed: 30482645 doi: 10.1016/j.schres.2018.10.022

Auteurs

Eva Velthorst (E)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. eva.velthorst@mssm.edu.
Seaver Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA. eva.velthorst@mssm.edu.
Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands. eva.velthorst@mssm.edu.

Josephine Mollon (J)

Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Robin M Murray (RM)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.

Lieuwe de Haan (L)

Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands.
Arkin Institute for Mental Health, Amsterdam, The Netherlands.

Inez Myin Germeys (IM)

Department of Neurosciences, Psychiatry Research Group, Center for Contextual Psychiatry, KU Leuven, Leuven, Belgium.

David C Glahn (DC)

Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish Mental Health Research Network (CIBERSAM), Madrid, Spain.

Els van der Ven (E)

Mailman School of Public Health, Columbia University, New York, NY, USA.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Marta Di Forti (M)

Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.
South London and Maudsley NHS Mental Health Foundation Trust, London, UK.

Miguel Bernardo (M)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.

Sinan Guloksuz (S)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.

Philippe Delespaul (P)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Mondriaan Mental Health Care, Heerlen/Maastricht, The Netherlands.

Gisela Mezquida (G)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.

Silvia Amoretti (S)

Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.

Julio Bobes (J)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.

Pilar A Saiz (PA)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.

María Paz García-Portilla (MP)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.

José Luis Santos (JL)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
Neurobiological Research Group, Institute of Technology, Universidad de Castilla-La Mancha, Cuenca, Spain.
Department of Psychiatry, Hospital "Virgen de la Luz", Cuenca, Spain.

Estela Jiménez-López (E)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.
Universidad de Castilla-La Mancha, Health and Social Research Center, Cuenca, Spain.

Julio Sanjuan (J)

Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain.

Eduardo J Aguilar (EJ)

Department of Psychiatry, Hospital Clínico Universitario de Valencia, INCLIVA, CIBERSAM, School of Medicine, Universidad de Valencia, Valencia, Spain.

Manuel Arrojo (M)

Department of Psychiatry, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

Angel Carracedo (A)

Grupo de Medicina Xenómica, Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Galician Health Service (SERGAS), Santiago de Compostela, Spain.
Centro de Investigación en Red de Enfermedades Raras (CIBERER) y Centro Nacional de Genotipado (CEGEN-PRB3), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.

Gonzalo López (G)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.

Javier González-Peñas (J)

Faculty of Medicine and Health Sciences - Psychiatry, Universidad de Oviedo, Mental Health Services of Principado de Asturias (SESPA), Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA), INEUROPA, CIBERSAM, Oviedo, Spain.

Mara Parellada (M)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish Mental Health Research Network (CIBERSAM), Madrid, Spain.

Cem Atbaşoğlu (C)

Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey.

Meram Can Saka (MC)

Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey.

Alp Üçok (A)

Department of Psychiatry, Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Köksal Alptekin (K)

Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.

Berna Akdede (B)

Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.

Tolga Binbay (T)

Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.

Vesile Altınyazar (V)

Department of Psychiatry, Adnan Menderes University, School of Medicine, Aydın, Turkey.

Halis Ulaş (H)

Department of Psychiatry, Dokuz Eylül University, School of Medicine, Izmir, Turkey.

Berna Yalınçetin (B)

Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.

Güvem Gümüş-Akay (G)

Department of Physiology, School of Medicine, Ankara University, Ankara, Turkey.
Brain Research Center, Ankara University, Ankara, Turkey.

Burçin Cihan Beyaz (BC)

Department of Psychology, Middle East Technical University, Ankara, Turkey.

Haldun Soygür (H)

Turkish Federation of Schizophrenia Associations, Ankara, Turkey.

Eylem Şahin Cankurtaran (EŞ)

Private Practice, Ankara, Turkey.

Semra Ulusoy Kaymak (SU)

Ankara City Hospital Psychiatry Clinic, Ankara, Turkey.

Nadja P Maric (NP)

Faculty of Medicine, University of Belgrade & Institute of Mental Health, Belgrade, Serbia.

Marina M Mihaljevic (MM)

Faculty of Medicine, University of Belgrade & Institute of Mental Health, Belgrade, Serbia.

Sanja Andric Petrovic (SA)

Faculty of Medicine, University of Belgrade & Clinic for Psychiatry, Belgrade, Serbia.

Tijana Mirjanic (T)

Special Hospital for Psychiatric Disorders Kovin, Kovin, Serbia.

Cristina Marta Del-Ben (CM)

Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Laura Ferraro (L)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.

Charlotte Gayer-Anderson (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.

Peter B Jones (PB)

Department of Psychiatry, University of Cambridge, Cambridge, England, UK.

Hannah E Jongsma (HE)

Department of Psychiatry, University of Cambridge, Cambridge, England, UK.
PsyLife Group, Division of Psychiatry, UCL, London, England, UK.

James B Kirkbride (JB)

PsyLife Group, Division of Psychiatry, UCL, London, England, UK.

Caterina La Cascia (C)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.

Antonio Lasalvia (A)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Sarah Tosato (S)

Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.

Pierre-Michel Llorca (PM)

Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.

Paulo Rossi Menezes (PR)

Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.

Craig Morgan (C)

Department of Health Service and Population Research, Institute of Psychiatry, King's College London, London, UK.
ESRC Centre for Society and Mental Health, King's College London, London, UK.

Diego Quattrone (D)

Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.

Marco Menchetti (M)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Jean-Paul Selten (JP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Rivierduinen Institute for Mental Health Care, Leiden, The Netherlands.

Andrei Szöke (A)

INSERM, U955, Créteil, France.

Ilaria Tarricone (I)

Department of Medical and Surgical Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.

Andrea Tortelli (A)

Etablissement Public de Santé Maison Blanche, Paris, France.

Philip McGuire (P)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.

Lucia Valmaggia (L)

Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Matthew J Kempton (MJ)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.

Mark van der Gaag (M)

Amsterdam Public Mental Health Research Institute, Department of Clinical Psychology, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Anita Riecher-Rössler (A)

Medizinische Fakultät, Universität Basel, Basel, Switzerland.

Rodrigo A Bressan (RA)

LiNC-Lab Interdisciplinar Neurociências Clínicas, Depto Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.

Neus Barrantes-Vidal (N)

Departament de Psicologia Clínica i de la Salut, Universitat Autònoma de Barcelona, Barcelona, Spain.
Fundació Sanitària Sant Pere Claver, Spanish Mental Health Research Network (CIBERSAM), Barcelona, Spain.

Barnaby Nelson (B)

Orygen, Parkville, VIC, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.

Patrick McGorry (P)

Orygen, Parkville, VIC, Australia.
Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Carlton South, VIC, Australia.

Chris Pantelis (C)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne & Melbourne Health, Carlton South, VIC, Australia.

Marie-Odile Krebs (MO)

University of Paris, GHU-Paris, Sainte-Anne, C'JAAD, Inserm U1266, Institut de Psychiatrie (CNRS 3557), Paris, France.

Stephan Ruhrmann (S)

Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.

Gabriele Sachs (G)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Bart P F Rutten (BPF)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim van Os (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, UK.
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Behrooz Z Alizadeh (BZ)

Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands.

Therese van Amelsvoort (T)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.

Agna A Bartels-Velthuis (AA)

University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands.

Richard Bruggeman (R)

University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands.
Department of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, The Netherlands.

Nico J van Beveren (NJ)

Antes Center for Mental Health Care, Rotterdam, The Netherlands.
Department of Psychiatry, Erasmus MC, Rotterdam, The Netherlands.
Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands.

Jurjen J Luykx (JJ)

Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Outpatient Second Opinion Clinic, GGNet Mental Health, Apeldoorn, The Netherlands.

Wiepke Cahn (W)

Department of Psychiatry, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Altrecht Science, Altrecht Mental Health Care, Utrecht, The Netherlands.

Claudia J P Simons (CJP)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
GGzE Institute for Mental Health Care, Eindhoven, The Netherlands.

Rene S Kahn (RS)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
VISN 2 Mental Illness Research, Education and Clinical Center (MIRECC), James J. Peters Department of Veterans Affairs Medical Center, New York, NY, USA.

Frederike Schirmbeck (F)

Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands.
Arkin Institute for Mental Health, Amsterdam, The Netherlands.

Ruud van Winkel (R)

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Neurosciences, Psychiatry Research Group, Center for Clinical Psychiatry, KU Leuven, Leuven, Belgium.

Abraham Reichenberg (A)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Seaver Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH